Toulose, France Clinical Trials

A listing of Toulose, France clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 137 clinical trials
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an activating EGFR mutation (exon 19 deletion or L858R) who have received and progressed on or after at least 1 EGFR TKI and 1 platinum-based chemotherapy-containing regimen.

Catalan Institute of Badalona Hospital Germans Trias i Pujol ICO
 (151.9 away) Contact site
  • 20 Jun, 2021
  • +84 other locations
A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease

The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on cognitive decline using the Alzheimer's Disease Assessment Scale Cognitive subscale 13-item version (ADAS-Cog13).

cognitive assessment
cognitive decline
alzheimer's disease
H pital Pellegrin CHU Bordeaux
 (131.5 away) Contact site
  • 03 Jun, 2021
  • +141 other locations
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors

Researchers are looking for a better way to treat people with solid tumors. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works. In this trial, the researchers want to learn about regorafenib taken together with nivolumab …

Institut Bergoni - Unicancer Nouvelle Aquitaine
 (131.0 away) Contact site
  • 18 Jun, 2021
  • +42 other locations
Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

Primary Objectives: To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function To assess the safety and tolerability of lademirsen (SAR339375) in subjects with Alport syndrome Secondary Objectives: To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites To assess the potential formation …

Investigational Site Number 7240001
 (154.0 away) Contact site
  • 01 May, 2021
  • +47 other locations
Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes

Type 1diabetes (T1D) is caused by autoimmune destruction of the pancreatic islet -cells, leading to an absolute deficiency in insulin. In health, regulatory T cells (Tregs) suppress immune responses against normal tissues, and likewise prevent autoimmune diseases. Tregs are insufficient in T1D. The investigators previously showed that administration of low …

autoimmune disease
treatment regimen
heart disease
Endocrinologie et diab tologie p diatrique, H pital des Enfants - CHU-Bordeaux
 (131.5 away) Contact site
  • 25 Jan, 2021
  • +43 other locations
Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

This is a Phase 2, open-label, multi-center study to evaluate the efficacy and the safety/tolerability of poziotinib in seven patient cohorts for up to 603 previously treated and treatment-nave NSCLC patients. Cohorts 3 and 4 were added with Amendment 1 and three additional cohorts were added with Amendment 2 (Cohorts …

stage iv non-small cell lung cancer
lung carcinoma
University Hospital Germans Trias i Pujol, Department of Medical Oncology
 (157.2 away) Contact site
  • 13 May, 2021
  • +68 other locations
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in HER2-mutated metastatic non-small cell lung cancer (NSCLC) participants who had disease recurrence or progression during/after at least one regimen of prior anticancer therapy (second line or later) that must have contained a platinum-based chemotherapy drug.

cancer chemotherapy
lung carcinoma
liquid biopsy
Hospital Universitario Vall d'Hebron
 (153.9 away) Contact site
  • 06 Jun, 2021
  • +52 other locations
Investigating Efficacy and Safety of Once-weekly NNC0195-0092 (Somapacitan) Treatment Compared to Daily Growth Hormone Treatment (Norditropin FlexPro ) in Growth Hormone Treatment na ve Pre-pubertal Children With Growth Hormone Deficiency

This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of once-weekly NNC0195-0092 (somapacitan) treatment compared to daily growth hormone treatment (Norditropin FlexPro) in growth hormone treatment nave pre-pubertal children with growth hormone deficiency. The trial consists of a 26 week main trial period, …

Novo Nordisk Investigational Site
 (2.0 away) Contact site
  • 09 May, 2021
  • +56 other locations
Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)

The aim of the phase II Nivothym study is to collect data on activity and toxicity of nivolumab therapy in patients with thymic carcinoma or type B3 thymoma that previously received a first platinum-based chemotherapy.

serum pregnancy test
chemotherapy regimen
thymic neoplasm
thymic carcinoma
renal function
CHU Toulouse - Hopital Larrey
 (0.5 away) Contact site
  • 18 Mar, 2021
  • +17 other locations
KRT-232 in Subjects With PMF Post-PV MF or Post-ET MF Who Have Failed a JAK Inhibitor

This study evaluates the efficacy in achieving clinical cure in non-bacteremic urinary tract infections (UTI) caused by Escherichia coli or Klebsiella pneumoniae producers of extended-spectrum -lactamases (ESBL) in adult patients. Half of participants will receive Piperacillin/Tazobactam as treatment, while the other half will receive Carbapenems. The investigators will verify that …

Institut Universitaire du Cancer de Toulouse Oncopole
 (0.5 away) Contact site
  • 23 Jan, 2021
  • +90 other locations